PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pulmatrix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.42+0.06 (+4.41%)
Close on Oct 19, 2026
- Market cap
- $5.19M
- P/E (TTM)
- –
- Dividend yield
- –
Pulmatrix, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 15 | Q3 15 | Q2 15 | % of revenue |
|---|---|---|---|---|
| Material Transfer Agreement [Member] | $38.00K | – | – | 100.0% |
| Tiotropium Bromide Collaboration Agreement [Member] | – | $651.00K | $170.00K | – |
By region
From the segment and revenue-disaggregation notes of Pulmatrix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.